PortalPublikationenCharacterization of a Pan-Immunoglobulin Assay Quantifying A...

Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study

Standard

Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. / Schaffner, Anna; Risch, Lorenz; Aeschbacher, Stefanie; Risch, Corina; Weber, Myriam C; Thiel, Sarah L; Jüngert, Katharina; Pichler, Michael; Grossmann, Kirsten; Wohlwend, Nadia; Lung, Thomas; Hillmann, Dorothea; Bigler, Susanna; Bodmer, Thomas; Imperiali, Mauro; Renz, Harald; Kohler, Philipp; Vernazza, Pietro; Kahlert, Christian R; Twerenbold, Raphael; Paprotny, Matthias; Conen, David; Risch, Martin.

in: J CLIN MED, Jahrgang 9, Nr. 12, 3989, 09.12.2020.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schaffner, A, Risch, L, Aeschbacher, S, Risch, C, Weber, MC, Thiel, SL, Jüngert, K, Pichler, M, Grossmann, K, Wohlwend, N, Lung, T, Hillmann, D, Bigler, S, Bodmer, T, Imperiali, M, Renz, H, Kohler, P, Vernazza, P, Kahlert, CR, Twerenbold, R, Paprotny, M, Conen, D & Risch, M 2020, 'Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study', J CLIN MED, Jg. 9, Nr. 12, 3989. https://doi.org/10.3390/jcm9123989

APA

Schaffner, A., Risch, L., Aeschbacher, S., Risch, C., Weber, M. C., Thiel, S. L., Jüngert, K., Pichler, M., Grossmann, K., Wohlwend, N., Lung, T., Hillmann, D., Bigler, S., Bodmer, T., Imperiali, M., Renz, H., Kohler, P., Vernazza, P., Kahlert, C. R., ... Risch, M. (2020). Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. J CLIN MED, 9(12), [3989]. https://doi.org/10.3390/jcm9123989

Vancouver

Schaffner A, Risch L, Aeschbacher S, Risch C, Weber MC, Thiel SL et al. Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. J CLIN MED. 2020 Dez 9;9(12). 3989. https://doi.org/10.3390/jcm9123989

Bibtex

@article{b91571d92cee4ebeac29f33dfe8c1947,
title = "Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study",
abstract = "Pan-immunoglobulin assays can simultaneously detect IgG, IgM and IgA directed against the receptor binding domain (RBD) of the S1 subunit of the spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 S1-RBD Ig). In this work, we aim to evaluate a quantitative SARS-CoV-2 S1-RBD Ig electrochemiluminescence immunoassay (ECLIA) regarding analytical, diagnostic, operational and clinical characteristics. Our work takes the form of a population-based study in the principality of Liechtenstein, including 125 cases with clinically well-described and laboratory confirmed SARS-CoV-2 infection and 1159 individuals without evidence of coronavirus disease 2019 (COVID-19). SARS-CoV-2 cases were tested for antibodies in sera taken with a median of 48 days (interquartile range, IQR, 43-52) and 139 days (IQR, 129-144) after symptom onset. Sera were also tested with other assays targeting antibodies against non-RBD-S1 and -S1/S2 epitopes. Sensitivity was 97.6% (95% confidence interval, CI, 93.2-99.1), whereas specificity was 99.8% (95% CI, 99.4-99.9). Antibody levels linearly decreased from hospitalized patients to symptomatic outpatients and SARS-CoV-2 infection without symptoms (p < 0.001). Among cases with SARS-CoV-2 infection, smokers had lower antibody levels than non-smokers (p = 0.04), and patients with fever had higher antibody levels than patients without fever (p = 0.001). Pan-SARS-CoV-2 S1-RBD Ig in SARS-CoV-2 infection cases significantly increased from first to second follow-up (p < 0.001). A substantial proportion of individuals without evidence of past SARS-CoV-2 infection displayed non-S1-RBD antibody reactivities (248/1159, i.e., 21.4%, 95% CI, 19.1-23.4). In conclusion, a quantitative SARS-CoV-2 S1-RBD Ig assay offers favorable and sustained assay characteristics allowing the determination of quantitative associations between clinical characteristics (e.g., disease severity, smoking or fever) and antibody levels. The assay could also help to identify individuals with antibodies of non-S1-RBD specificity with potential clinical cross-reactivity to SARS-CoV-2.",
author = "Anna Schaffner and Lorenz Risch and Stefanie Aeschbacher and Corina Risch and Weber, {Myriam C} and Thiel, {Sarah L} and Katharina J{\"u}ngert and Michael Pichler and Kirsten Grossmann and Nadia Wohlwend and Thomas Lung and Dorothea Hillmann and Susanna Bigler and Thomas Bodmer and Mauro Imperiali and Harald Renz and Philipp Kohler and Pietro Vernazza and Kahlert, {Christian R} and Raphael Twerenbold and Matthias Paprotny and David Conen and Martin Risch",
year = "2020",
month = dec,
day = "9",
doi = "10.3390/jcm9123989",
language = "English",
volume = "9",
journal = "J CLIN MED",
issn = "2077-0383",
publisher = "MDPI AG",
number = "12",

}

RIS

TY - JOUR

T1 - Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study

AU - Schaffner, Anna

AU - Risch, Lorenz

AU - Aeschbacher, Stefanie

AU - Risch, Corina

AU - Weber, Myriam C

AU - Thiel, Sarah L

AU - Jüngert, Katharina

AU - Pichler, Michael

AU - Grossmann, Kirsten

AU - Wohlwend, Nadia

AU - Lung, Thomas

AU - Hillmann, Dorothea

AU - Bigler, Susanna

AU - Bodmer, Thomas

AU - Imperiali, Mauro

AU - Renz, Harald

AU - Kohler, Philipp

AU - Vernazza, Pietro

AU - Kahlert, Christian R

AU - Twerenbold, Raphael

AU - Paprotny, Matthias

AU - Conen, David

AU - Risch, Martin

PY - 2020/12/9

Y1 - 2020/12/9

N2 - Pan-immunoglobulin assays can simultaneously detect IgG, IgM and IgA directed against the receptor binding domain (RBD) of the S1 subunit of the spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 S1-RBD Ig). In this work, we aim to evaluate a quantitative SARS-CoV-2 S1-RBD Ig electrochemiluminescence immunoassay (ECLIA) regarding analytical, diagnostic, operational and clinical characteristics. Our work takes the form of a population-based study in the principality of Liechtenstein, including 125 cases with clinically well-described and laboratory confirmed SARS-CoV-2 infection and 1159 individuals without evidence of coronavirus disease 2019 (COVID-19). SARS-CoV-2 cases were tested for antibodies in sera taken with a median of 48 days (interquartile range, IQR, 43-52) and 139 days (IQR, 129-144) after symptom onset. Sera were also tested with other assays targeting antibodies against non-RBD-S1 and -S1/S2 epitopes. Sensitivity was 97.6% (95% confidence interval, CI, 93.2-99.1), whereas specificity was 99.8% (95% CI, 99.4-99.9). Antibody levels linearly decreased from hospitalized patients to symptomatic outpatients and SARS-CoV-2 infection without symptoms (p < 0.001). Among cases with SARS-CoV-2 infection, smokers had lower antibody levels than non-smokers (p = 0.04), and patients with fever had higher antibody levels than patients without fever (p = 0.001). Pan-SARS-CoV-2 S1-RBD Ig in SARS-CoV-2 infection cases significantly increased from first to second follow-up (p < 0.001). A substantial proportion of individuals without evidence of past SARS-CoV-2 infection displayed non-S1-RBD antibody reactivities (248/1159, i.e., 21.4%, 95% CI, 19.1-23.4). In conclusion, a quantitative SARS-CoV-2 S1-RBD Ig assay offers favorable and sustained assay characteristics allowing the determination of quantitative associations between clinical characteristics (e.g., disease severity, smoking or fever) and antibody levels. The assay could also help to identify individuals with antibodies of non-S1-RBD specificity with potential clinical cross-reactivity to SARS-CoV-2.

AB - Pan-immunoglobulin assays can simultaneously detect IgG, IgM and IgA directed against the receptor binding domain (RBD) of the S1 subunit of the spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 S1-RBD Ig). In this work, we aim to evaluate a quantitative SARS-CoV-2 S1-RBD Ig electrochemiluminescence immunoassay (ECLIA) regarding analytical, diagnostic, operational and clinical characteristics. Our work takes the form of a population-based study in the principality of Liechtenstein, including 125 cases with clinically well-described and laboratory confirmed SARS-CoV-2 infection and 1159 individuals without evidence of coronavirus disease 2019 (COVID-19). SARS-CoV-2 cases were tested for antibodies in sera taken with a median of 48 days (interquartile range, IQR, 43-52) and 139 days (IQR, 129-144) after symptom onset. Sera were also tested with other assays targeting antibodies against non-RBD-S1 and -S1/S2 epitopes. Sensitivity was 97.6% (95% confidence interval, CI, 93.2-99.1), whereas specificity was 99.8% (95% CI, 99.4-99.9). Antibody levels linearly decreased from hospitalized patients to symptomatic outpatients and SARS-CoV-2 infection without symptoms (p < 0.001). Among cases with SARS-CoV-2 infection, smokers had lower antibody levels than non-smokers (p = 0.04), and patients with fever had higher antibody levels than patients without fever (p = 0.001). Pan-SARS-CoV-2 S1-RBD Ig in SARS-CoV-2 infection cases significantly increased from first to second follow-up (p < 0.001). A substantial proportion of individuals without evidence of past SARS-CoV-2 infection displayed non-S1-RBD antibody reactivities (248/1159, i.e., 21.4%, 95% CI, 19.1-23.4). In conclusion, a quantitative SARS-CoV-2 S1-RBD Ig assay offers favorable and sustained assay characteristics allowing the determination of quantitative associations between clinical characteristics (e.g., disease severity, smoking or fever) and antibody levels. The assay could also help to identify individuals with antibodies of non-S1-RBD specificity with potential clinical cross-reactivity to SARS-CoV-2.

U2 - 10.3390/jcm9123989

DO - 10.3390/jcm9123989

M3 - SCORING: Journal article

C2 - 33317059

VL - 9

JO - J CLIN MED

JF - J CLIN MED

SN - 2077-0383

IS - 12

M1 - 3989

ER -